Prof. Rolf Teschke is an internationally recognized expert in hepatology whose distinguished career has significantly influenced contemporary understanding of liver diseases, hepatotoxicity, and drug-induced liver injury. Educated at leading medical institutions and trained in internal medicine with specialization in gastroenterology and hepatology, he advanced early in his career through rigorous scientific and clinical environments that shaped his enduring interest in hepatic metabolism and toxicology. His research journey includes extensive work in experimental hepatology, where he contributed pivotal insights into microsomal ethanol-oxidizing systems, cytochrome P450 related pathways, and the biochemical mechanisms underlying alcohol-associated and toxin-induced liver damage. Over several decades, Prof. Rolf Teschke has held prominent academic and clinical positions, leading major medical departments and contributing to both patient care and research innovation. His expertise is particularly well known for advancing causality assessment methodologies in drug-induced liver injury, especially through his influential work with the RUCAM system, which has become a globally referenced tool in hepatotoxicity evaluation. Throughout his career, he has produced a substantial body of peer-reviewed literature, reflecting profound scientific productivity and impact. His publication record includes 171 documents, supported by 6,888 citations across 4,040 citing documents, and an impressive h-index of 48, underscoring the depth, relevance, and international recognition of his work. Prof. Rolf Teschke’s research interests span alcoholic liver disease, herbal and drug hepatotoxicity, biochemical enzymology, and clinical hepatology, integrating laboratory discoveries with real-world clinical applications to improve diagnostic standards and therapeutic strategies. He has authored and co-authored more than 250 publications, including articles, book chapters, and comprehensive reviews, contributing to foundational knowledge used by clinicians, toxicologists, and regulatory bodies worldwide. In addition to research, he has served in editorial roles for several journals, helping guide scientific discourse in hepatology and liver toxicology. Overall, Prof. Rolf Teschke’s career reflects a sustained commitment to advancing scientific excellence, improving patient outcomes, and shaping global best practices in the study of liver injury, marking him as one of the leading contributors to modern hepatology.
Profile; Scopus | Orcid
Featured Publications:
Teschke, R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Review.
Annotation: Discusses two-step autoimmune hepatitis triggered by pharmaceutical agents, highlighting diagnostic and clinical implications.
Teschke, R. Acute Liver Failure with Determinate rather than Indeterminate Etiology Facilitates Therapy and May Avoid Liver Transplantation: A Critical Analysis. Review.
Annotation: Evaluates clinical outcomes in acute liver failure and argues the benefits of precise etiological identification.
Teschke, R., et al. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Review.
Annotation: Compares two validated diagnostic algorithms to strengthen causality assessment in drug-induced autoimmune hepatitis.
Teschke, R. Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification. Review.
Annotation: Proposes an evidence-based immunological classification for idiosyncratic drug-induced liver injury (DILI).
Teschke, R., et al. Metabolic Mysteries of Copper Dysregulation in Wilson Disease. Review.
Annotation: Explores metabolic pathways and unresolved mechanisms underlying copper dysregulation in Wilson’s disease.
Teschke, R., et al. Open Questions on How Metabolic Dysfunction-Associated Steatotic Liver Disease Shapes the Course of Drug-Induced Liver Injury. Letter.
Annotation: Raises key unresolved scientific and clinical questions on the interaction between MASLD and DILI.
Teschke, R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. Review.
Annotation: Introduces a new five-type classification system for liver injury associated with severe immune-mediated skin reactions.
Teschke, R. Acute Liver Failure Due to Assumed Drug Induced Liver Injury but Lack of Any Validated Causality Algorithm: Evidence by 36 Cohort Reports with 21,709 Cases. Review.
Annotation: Critically analyzes large cohorts revealing gaps in validated causality assessment for assumed DILI-related acute liver failure.
Teschke, R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on RUCAM and HLA B57:01 Genotype.* Review.
Annotation: Examines metabolic and immune mechanisms underlying flucloxacillin-induced hepatocellular injury.
Teschke, R., et al. Successful Corticosteroid Therapy for Severe Liver Injury Secondary to Herbal Traditional Chinese Medicine Mega Defends X: A Case Report. Article, 2024.
Annotation: Documents a clinically significant case showing steroid responsiveness in herb-induced liver injury assessed by updated RUCAM.